- Home
- BEAT vs CVM Comparison
BEAT vs CVM Comparison
Compare BEAT & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- CVM
- Stock Information
- Founded
- BEAT 2015
- CVM 1983
- Country
- BEAT United States
- CVM United States
- Employees
- BEAT N/A
- CVM N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BEAT Technology
- CVM Health Care
- Exchange
- BEAT Nasdaq
- CVM Nasdaq
- Market Cap
- BEAT 59.8M
- CVM 68.9M
- IPO Year
- BEAT 2021
- CVM 1987
- Fundamental
- Price
- BEAT $2.22
- CVM $0.94
- Analyst Decision
- BEAT Buy
- CVM
- Analyst Count
- BEAT 1
- CVM 0
- Target Price
- BEAT $8.00
- CVM N/A
- AVG Volume (30 Days)
- BEAT 78.6K
- CVM 252.7K
- Earning Date
- BEAT 11-12-2024
- CVM 08-15-2024
- Dividend Yield
- BEAT N/A
- CVM N/A
- EPS Growth
- BEAT N/A
- CVM N/A
- EPS
- BEAT N/A
- CVM N/A
- Revenue
- BEAT N/A
- CVM N/A
- Revenue This Year
- BEAT N/A
- CVM N/A
- Revenue Next Year
- BEAT N/A
- CVM $3,412.81
- P/E Ratio
- BEAT N/A
- CVM N/A
- Revenue Growth
- BEAT N/A
- CVM N/A
- 52 Week Low
- BEAT $1.06
- CVM $0.93
- 52 Week High
- BEAT $3.39
- CVM $3.23
- Technical
- Relative Strength Index (RSI)
- BEAT 49.47
- CVM 33.61
- Support Level
- BEAT $2.06
- CVM $0.93
- Resistance Level
- BEAT $2.30
- CVM $1.13
- Average True Range (ATR)
- BEAT 0.13
- CVM 0.04
- MACD
- BEAT 0.01
- CVM -0.01
- Stochastic Oscillator
- BEAT 47.76
- CVM 6.55
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.